Abstract
Background: Breast cancer is the commonest cancer among women in India with 162468 new cases diagnosed in 2018. Triple-negative breast cancer accounts for 20–30% of these cases. It is a heterogeneous and poorly understood disease that has worse outcomes as compared to the other subtypes of breast cancer. Carboplatin has been shown to improve outcomes in the neoadjuvant setting in early triple-negative breast cancer. Studies on cisplatin in the neoadjuvant setting, especially in combination with anthracyclines and taxanes are very few. This study analysed the safety and efficacy of neoadjuvant cisplatin-based combination chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
